Monday, November 6, 2017
- 9:00AM-11:00AM
-
Abstract Number: 1033
Burden of Illness in Patients with RA and Anti-Cyclic Citrullinated Peptide Positivity
Health Services Research Poster II: Osteoarthritis and Rheumatoid Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1437
C-Reactive Protein Levels in Patients with or without Structural Progression: A Post-Hoc Analysis from a Phase 3 Tofacitinib Trial
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports- 9:00AM-11:00AM
-
Abstract Number: 1635
Cachexia in Systemic Lupus Erythematosus- an Underrecognized Syndrome
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 1218
Caffeine Consumption and Risk of Osteoporosis: A Cross Sectional Study of 3, 210 Patients from the National Health and Nutrition Examination Survey
Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster II- 9:00AM-11:00AM
-
Abstract Number: 1396
Can 3 0-10 Physician Visual Analog Scales (VAS) to Assess Levels of Inflammation, Damage and Distress Offer Comprehensive Quantitative Data That May be As Informative As Detailed, Formal Swollen and Tender Joint Counts?
Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures- 9:00AM-11:00AM
-
Abstract Number: 1130
Can Alcohol Intake in Moderation Lower the Risk of Myocardial Infarction and Mortality Even Among Gout Patients?
Metabolic and Crystal Arthropathies Poster I- 9:00AM-11:00AM
-
Abstract Number: 1701
Can Durometer Differentiate Limited Versus Diffuse Cutaneous Systemic Sclerosis?
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster II- 9:00AM-11:00AM
-
Abstract Number: 1606
Cancer in an SLE Inception Cohort: Smoking May out-Perform Tumor Markers As a Risk Predictor
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 976
Cannabinoid Receptor 2 Agonist (JWH-015) Inhibits Interleukin-1β-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts
Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster II: Mesenchymal Cells Do React - But How?- 9:00AM-11:00AM
-
Abstract Number: 1061
Cardiac Endothelial Cell Transcriptome Analyses Support a Pathological Role of Metabolic and Inflammasome Genes in Anti-SSA/Ro-Associated Congenital Heart Block
Innate Immunity and Rheumatic Disease Poster II- 9:00AM-11:00AM
-
Abstract Number: 1646
Cardiovascular disease in Systemic Lupus Erythematosus. The road to hell is paved with good intentions
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 1490
Cardiovascular Morbidity and Mortality in Primary Sjögren Syndrome: A Systematic Review and Meta-Analysis
Sjögren's Syndrome Poster II: Clinical Research- 9:00AM-11:00AM
-
Abstract Number: 1748
Cbl-b Associates with Bcl-6 and Is Differentially Expressed in Circulating Follicular T Helper Cells of Patients with Systemic Lupus Erythematosus
T Cell Biology and Targets in Autoimmune Disease Poster I- 9:00AM-11:00AM
-
Abstract Number: 1518
Certolizumab Pegol Effectiveness and Retention Rate in Psoriatic Arthritis. Real Life Data